Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

A Taxon-Specific and High-Throughput Method for Measuring Ligand Binding to Nicotinic Acetylcholine Receptors.

Zdenek CN, Harris RJ, Kuruppu S, Youngman NJ, Dobson JS, Debono J, Khan M, Smith I, Yarski M, Harrich D, Sweeney C, Dunstan N, Allen L, Fry BG.

Toxins (Basel). 2019 Oct 16;11(10). pii: E600. doi: 10.3390/toxins11100600.

2.

Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant.

Jin H, Sun Y, Li D, Lin MH, Lor M, Rustanti L, Harrich D.

MBio. 2019 Aug 27;10(4). pii: e01769-19. doi: 10.1128/mBio.01769-19.

3.

Oxazole-Benzenesulfonamide Derivatives Inhibit HIV-1 Reverse Transcriptase Interaction with Cellular eEF1A and Reduce Viral Replication.

Rawle DJ, Li D, Wu Z, Wang L, Choong M, Lor M, Reid RC, Fairlie DP, Harris J, Tachedjian G, Poulsen SA, Harrich D.

J Virol. 2019 May 29;93(12). pii: e00239-19. doi: 10.1128/JVI.00239-19. Print 2019 Jun 15.

PMID:
30918071
4.

eEF1A demonstrates paralog specific effects on HIV-1 reverse transcription efficiency.

Li D, Rawle DJ, Wu Z, Jin H, Lin MH, Lor M, Abbott CM, Harrich D.

Virology. 2019 Apr;530:65-74. doi: 10.1016/j.virol.2019.01.023. Epub 2019 Jan 29.

PMID:
30782564
5.

The eukaryotic translation elongation factor 1A regulation of actin stress fibers is important for infectious RSV production.

Snape N, Li D, Wei T, Jin H, Lor M, Rawle DJ, Spann KM, Harrich D.

Virol J. 2018 Nov 26;15(1):182. doi: 10.1186/s12985-018-1091-7.

6.

Toward the "unravelling" of HIV: Host cell factors involved in HIV-1 core uncoating.

Rawle DJ, Harrich D.

PLoS Pathog. 2018 Oct 4;14(10):e1007270. doi: 10.1371/journal.ppat.1007270. eCollection 2018 Oct. No abstract available.

7.

HIV-1 Uncoating and Reverse Transcription Require eEF1A Binding to Surface-Exposed Acidic Residues of the Reverse Transcriptase Thumb Domain.

Rawle DJ, Li D, Swedberg JE, Wang L, Soares DC, Harrich D.

MBio. 2018 Mar 27;9(2). pii: e00316-18. doi: 10.1128/mBio.00316-18.

8.

RNA glycosidase and other agents target Tat to inhibit HIV-1 transcription.

Harrich D, Jin H.

Biochem J. 2018 Mar 20;475(6):1059-1062. doi: 10.1042/BCJ20170669.

PMID:
29559581
9.

Differential Effects of Strategies to Improve the Transduction Efficiency of Lentiviral Vector that Conveys an Anti-HIV Protein, Nullbasic, in Human T Cells.

Rustanti L, Jin H, Li D, Lor M, Sivakumaran H, Harrich D.

Virol Sin. 2018 Apr;33(2):142-152. doi: 10.1007/s12250-018-0004-7. Epub 2018 Mar 14.

10.

A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes.

Rustanti L, Jin H, Lor M, Lin MH, Rawle DJ, Harrich D.

Virol J. 2017 Mar 14;14(1):52. doi: 10.1186/s12985-017-0705-9.

11.

Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein.

Jin H, Li D, Sivakumaran H, Lor M, Rustanti L, Cloonan N, Wani S, Harrich D.

MBio. 2016 Jul 5;7(4). pii: e00518-16. doi: 10.1128/mBio.00518-16.

12.

Specific Interaction between eEF1A and HIV RT Is Critical for HIV-1 Reverse Transcription and a Potential Anti-HIV Target.

Li D, Wei T, Rawle DJ, Qin F, Wang R, Soares DC, Jin H, Sivakumaran H, Lin MH, Spann K, Abbott CM, Harrich D.

PLoS Pathog. 2015 Dec 1;11(12):e1005289. doi: 10.1371/journal.ppat.1005289. eCollection 2015 Dec.

13.

The protein arginine methyltransferase PRMT6 inhibits HIV-1 Tat nucleolar retention.

Fulcher AJ, Sivakumaran H, Jin H, Rawle DJ, Harrich D, Jans DA.

Biochim Biophys Acta. 2016 Feb;1863(2):254-62. doi: 10.1016/j.bbamcr.2015.11.019. Epub 2015 Dec 2.

14.

Binding of the eukaryotic translation elongation factor 1A with the 5'UTR of HIV-1 genomic RNA is important for reverse transcription.

Li D, Wei T, Jin H, Rose A, Wang R, Lin MH, Spann K, Harrich D.

Virol J. 2015 Aug 6;12:118. doi: 10.1186/s12985-015-0337-x.

15.

A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.

Lin MH, Apolloni A, Cutillas V, Sivakumaran H, Martin S, Li D, Wei T, Wang R, Jin H, Spann K, Harrich D.

J Virol. 2015 May;89(9):4827-36. doi: 10.1128/JVI.03440-14. Epub 2015 Feb 11.

16.

A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1.

Lin MH, Sivakumaran H, Jones A, Li D, Harper C, Wei T, Jin H, Rustanti L, Meunier FA, Spann K, Harrich D.

Retrovirology. 2014 Dec 14;11:121. doi: 10.1186/s12977-014-0121-9.

17.

The eukaryotic elongation factor 1A is critical for genome replication of the paramyxovirus respiratory syncytial virus.

Wei T, Li D, Marcial D, Khan M, Lin MH, Snape N, Ghildyal R, Harrich D, Spann K.

PLoS One. 2014 Dec 5;9(12):e114447. doi: 10.1371/journal.pone.0114447. eCollection 2014.

18.

Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.

Dang NT, Sivakumaran H, Harrich D, Shaw PN, Davis-Poynter N, Coombes AG.

Eur J Pharm Biopharm. 2014 Oct;88(2):406-14. doi: 10.1016/j.ejpb.2014.05.018. Epub 2014 Jun 2.

PMID:
24887313
19.

Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission.

Dang N, Sivakumaran H, Harrich D, Shaw PN, Coombes AGA.

J Pharm Sci. 2014 Jul;103(7):2107-2115. doi: 10.1002/jps.24030. Epub 2014 May 27.

PMID:
24867411
20.

Sensor for early detection of wound infection.

Hajnsek M, Harrich D, Schiffer D, Guebitz G, Sinner F.

Biomed Tech (Berl). 2013 Aug;58 Suppl 1. pii: /j/bmte.2013.58.issue-s1-F/bmt-2013-4147/bmt-2013-4147.xml. doi: 10.1515/bmt-2013-4147. Epub 2013 Sep 7. No abstract available.

PMID:
24042782
21.

An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV.

Dang NT, Sivakumaran H, Harrich D, Coombes AG.

J Pharm Sci. 2013 Oct;102(10):3725-35. doi: 10.1002/jps.23684. Epub 2013 Jul 31.

PMID:
23904196
22.

Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6.

Sivakumaran H, Lin MH, Apolloni A, Cutillas V, Jin H, Li D, Wei T, Harrich D.

Virol J. 2013 Jun 24;10:207. doi: 10.1186/1743-422X-10-207.

23.

The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis.

Li D, Wei T, Abbott CM, Harrich D.

Microbiol Mol Biol Rev. 2013 Jun;77(2):253-66. doi: 10.1128/MMBR.00059-12. Review.

24.

Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication.

da Silva FA, Li M, Rato S, Maia S, Malhó R, Warren K, Harrich D, Craigie R, Barbas C 3rd, Goncalves J.

Biotechnol Appl Biochem. 2012 Sep-Oct;59(5):353-66. doi: 10.1002/bab.1034. Epub 2012 Oct 10.

25.

A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Apolloni A, Lin MH, Sivakumaran H, Li D, Kershaw MH, Harrich D.

Hum Gene Ther. 2013 Mar;24(3):270-82. doi: 10.1089/hum.2012.176. Epub 2013 Mar 1.

26.

Nullbasic, a potent anti-HIV tat mutant, induces CRM1-dependent disruption of HIV rev trafficking.

Lin MH, Sivakumaran H, Apolloni A, Wei T, Jans DA, Harrich D.

PLoS One. 2012;7(12):e51466. doi: 10.1371/journal.pone.0051466. Epub 2012 Dec 10.

27.

Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors.

Warren K, Wei T, Li D, Qin F, Warrilow D, Lin MH, Sivakumaran H, Apolloni A, Abbott CM, Jones A, Anderson JL, Harrich D.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9587-92. doi: 10.1073/pnas.1204673109. Epub 2012 May 24.

28.

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.

Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA.

Biochem J. 2012 May 1;443(3):851-6. doi: 10.1042/BJ20120150.

29.

Strand transfer and elongation of HIV-1 reverse transcription is facilitated by cell factors in vitro.

Warrilow D, Warren K, Harrich D.

PLoS One. 2010 Oct 6;5(10):e13229. doi: 10.1371/journal.pone.0013229.

30.

Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription.

Warren K, Warrilow D, Meredith L, Harrich D.

Viruses. 2009 Dec;1(3):873-94. doi: 10.3390/v1030873. Epub 2009 Nov 10.

31.

Potent inhibition of HIV-1 replication by a Tat mutant.

Meredith LW, Sivakumaran H, Major L, Suhrbier A, Harrich D.

PLoS One. 2009 Nov 10;4(11):e7769. doi: 10.1371/journal.pone.0007769.

32.

Maturation of the HIV reverse transcription complex: putting the jigsaw together.

Warrilow D, Tachedjian G, Harrich D.

Rev Med Virol. 2009 Nov;19(6):324-37. doi: 10.1002/rmv.627. Review.

PMID:
19750561
33.

Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat.

Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D.

J Virol. 2009 Nov;83(22):11694-703. doi: 10.1128/JVI.00499-09. Epub 2009 Sep 2.

34.

Human immunodeficiency virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells.

Davis AJ, Carr JM, Bagley CJ, Powell J, Warrilow D, Harrich D, Burrell CJ, Li P.

Retrovirology. 2008 Dec 18;5:115. doi: 10.1186/1742-4690-5-115.

35.

Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro.

Warrilow D, Meredith L, Davis A, Burrell C, Li P, Harrich D.

J Virol. 2008 Feb;82(3):1425-37. Epub 2007 Nov 28.

36.

Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort.

Sivakumaran H, Wang B, Gill MJ, Beckholdt B, Saksena NK, Harrich D.

Virol J. 2007 Oct 25;4:107.

37.

Isolated HIV-1 core is active for reverse transcription.

Warrilow D, Stenzel D, Harrich D.

Retrovirology. 2007 Oct 24;4:77.

38.

The HIV-1 Tat protein stimulates reverse transcription in vitro.

Apolloni A, Meredith LW, Suhrbier A, Kiernan R, Harrich D.

Curr HIV Res. 2007 Sep;5(5):473-83.

PMID:
17896967
39.

HIV-1 replication from after cell entry to the nuclear periphery.

Warrilow D, Harrich D.

Curr HIV Res. 2007 May;5(3):293-9.

PMID:
17504171
40.

Protein methylation is required to maintain optimal HIV-1 infectivity.

Willemsen NM, Hitchen EM, Bodetti TJ, Apolloni A, Warrilow D, Piller SC, Harrich D.

Retrovirology. 2006 Dec 15;3:92.

41.

Will diverse Tat interactions lead to novel antiretroviral drug targets?

Harrich D, McMillan N, Munoz L, Apolloni A, Meredith L.

Curr Drug Targets. 2006 Dec;7(12):1595-606. Review.

PMID:
17168834
42.

HIV type 1 inhibition by protein kinase C modulatory compounds.

Warrilow D, Gardner J, Darnell GA, Suhrbier A, Harrich D.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):854-64.

PMID:
16989610
43.

SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication.

Darnell GA, Schroder WA, Gardner J, Harrich D, Yu H, Medcalf RL, Warrilow D, Antalis TM, Sonza S, Suhrbier A.

J Biol Chem. 2006 Oct 20;281(42):31348-58. Epub 2006 Aug 21.

44.

Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription.

Endo-Munoz L, Warby T, Harrich D, McMillan NA.

Virol J. 2005 Feb 28;2:17.

45.

Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D, Suhrbier A.

Mol Cell Biol. 2003 Sep;23(18):6520-32.

47.

Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Harvey TJ, Anraku I, Linedale R, Harrich D, Mackenzie J, Suhrbier A, Khromykh AA.

J Virol. 2003 Jul;77(14):7796-803.

49.

Human immunodeficiency virus type 1 reverse transcription is stimulated by tat from other lentiviruses.

Hooker CW, Scott J, Apolloni A, Parry E, Harrich D.

Virology. 2002 Sep 1;300(2):226-35.

50.

Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Anraku I, Harvey TJ, Linedale R, Gardner J, Harrich D, Suhrbier A, Khromykh AA.

J Virol. 2002 Apr;76(8):3791-9.

Supplemental Content

Loading ...
Support Center